Table 1 Lipophilicity (log Kw), cell permeability and EIA/RIA specificity of selected cyclic Nucleotide analogs.
Analog | Log Kw | Permeability | Specificity ENZO cAMP-EIA | Specificity ENZO cAMP-EIA | Specificity IBL cGMP-RIA | Specificity Cayman cGMP-EIA |
|---|---|---|---|---|---|---|
2’-dcGMP | 0.65 | 0% | 5.21% | |||
cGMP | 0.77 | 100% | 100% | 100% | ||
Rp-cGMPS | 0.89 | 0.27% | 10.6% | |||
2’-dcAMP | 0% | 2.4% | ||||
cAMP | 1.09 | 100% | ||||
8-Br-cGMP | 1.17 | 12.1% | 490% | 20% | 0.5% | |
Rp-cAMPS | 1.21 | 12.2% | 68% | |||
8-Br-cAMP | 1.35 | 8.0% | 0.4% | |||
Rp-8-Br-cAMPS | 1.47 | 0.3% | ||||
6-MB-cAMP | 1.64 | 0.4% | ||||
6-Bnz-cAMP | 1.9 | 0.6% | ||||
8-pCPT-cGMP | 2.52 | 19.6% | 240% | 30% | 0.008% | |
8-pCPT-cAMP | 2.65 | 22.0% | 0.05% | |||
8-Br-PET-cGMP | 2.83 | 30.9% | 10% | 0.15% | 1.6% | |
Rp-8-Br-PET-cGMPS | 2.83 | 0.2% | ||||
8-pCPT-2’-OMe-cAMP (Epac Activator) | 2.94 | 0.03% | 0.02% | |||
Sp-5,6-DCI-cBIMPS | 2.99 | <0.001% |